Efficacy News and Research

RSS

Scientists Identify EHMT2 Enzyme as Main Cause of 5-FU Failure

One of the most widely used chemotherapeutic agents for colorectal cancer is 5-fluorouracil (5-FU), a cornerstone treatment that has improved outcomes for countless patients.

9 Jun 2026

Creatine Linked to Cancer-Fighting Dendritic Cell Function

According to recent UCLA research, creatine, the organic acid that athletes and bodybuilders frequently use as a supplement, supercharges a crucial class of immune cells that activate and prime the body's primary cancer-fighting agents.

8 Jun 2026

Bispecific Antibodies Target Tumors While Sparing Healthy Tissue

A new generation of bispecific antibodies effectively targets cancer cells, minimizing toxicity and enhancing treatment precision in preclinical studies.

3 Jun 2026

Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

New TriPcide Antibiotics Kill Dormant MRSA Without Resistance

The study on TriPcides reveals their ability to combat MRSA and dormant bacteria, offering a new strategy to address antimicrobial resistance in public health.

27 May 2026

Polymer Platforms Help Focus Immune Attack on Cancerous Tumors

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Genetic Engineering Creates an Immune System Cloak to Extend Bacterial Drug Circulation

While previous research from Johns Hopkins University is successfully completing clinical trials, University of Rhode Island College of Pharmacy Assistant Professor Kaitlin Dailey is expanding on that work to more specifically target tumors that are difficult or impossible to access, especially those associated with pancreatic cancer-one of the deadliest types.

21 May 2026

New 3D Cortical Tissue Models Incorporate Microglia to Bridge Preclinical Translation Gaps

28bio today announced CNS-3D Inflammatory Organoids, designed to evaluate efficacy of anti-inflammatory drugs by quantifying their ability to reduce inflammatory injury, preserve tissue health, and restore neuronal network activity.

20 May 2026

Restricted Interaction Peptides Change Shape to Lock Therapy Inside Solid Tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target.

14 May 2026

X-Ray Finds Hidden Metal in Beef Where Metal Detectors and Ultrasound Fall Short

X-ray imaging detected all ten embedded metallic objects across tested beef tissue depths and muscle states, outperforming both traditional metal detection and ultrasound. Metal detection worked mainly for larger, shallower objects, while ultrasound showed limited value for detecting foreign metallic materials in beef carcasses.

13 May 2026

New CRISPR System Destroys Diseased Cells With High Precision

A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while leaving healthy cells untouched.

8 May 2026

AI Designs New Antibiotics That Reduce MRSA Infections In Mice

SyntheMol-RL integrates reinforcement learning for antibiotic design, producing synthesizable candidates that show efficacy against MRSA in preclinical models.

5 May 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC).

From MRM Health NV 4 May 2026

Force-Sensing Microgripper Enables Safe Handling of Cell Spheroids

In tissue engineering, the tiniest bit of improper force can harm a living culture. 3D clumps of cells - known as spheroids - can be used to model complex human tissues, because they can re-create specific cell-to-cell and cell-to-matrix interactions.

30 Apr 2026

How the Microbiome Shapes Cancer Immunity and Therapy Response

This review examines how the human microbiome regulates anti-tumor immunity through DNA damage, inflammation, immune-cell activity, microbial metabolites, and tumor microenvironment remodeling. It highlights emerging microbiome-based strategies, including FMT, probiotics, prebiotics, engineered bacteria, and live biotherapeutics, while stressing the need for rigorous validation and clinical trials.

29 Apr 2026

Molecular Keyhole Discovery Unlocks New Target for Pain Therapies

Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular 'keyhole', in the TRPM3 ion channel, a crucial sensor in pain signaling.

22 Apr 2026

New Data Demonstrates the Unique Scalability of Evaxion’s AI-Immunology™ Platform in Glioblastoma

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform’s ability to also potentially develop vaccines for glioblastoma (brain cancer).

From Evaxion A/S 21 Apr 2026

How Mitochondrial Damage Accelerates Stem Cell Aging

Hematopoietic stem cells (HSCs), the cells that produce all blood cell types, start to lose their efficacy as one ages, which eventually reduces the ability to maintain healthy blood and a robust immune system.

17 Apr 2026

Researchers Develop 3D Organoids that Reflect the Complexity of Brain Tumors

Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, scientists at St. Jude Children's Research Hospital developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.

16 Apr 2026

Semen-Derived Exosomes Eye Drops to Treat Retinoblastoma

Innovative eye drops using semen-derived exosomes target retinoblastoma, improving therapeutic delivery and preserving ocular function in preclinical models.

8 Apr 2026